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Fibroblasts as Target Cells for DEB 
Gene Therapy
Mei Chen1 and David T. Woodley1
Dystrophic epidermolysis bullosa (DEB) is due to mutations in the type VII col-
lagen (C7) gene. Potential therapies for DEB include (i) ex vivo gene therapy and 
(ii) intradermal injection of gene-corrected DEB fibroblasts, lentiviral vectors 
expressing C7 or recombinant C7 itself. With regard to molecular engineering, 
the dermal fibroblast has advantages over epidermal keratinocytes for deliver-
ing C7 to DEB patients.
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The study in this issue by Goto and 
colleagues (2006) at the Hokkaido 
University Graduate School of 
Medicine makes a case that the tar-
get for gene therapy for dystrophic 
epidermolysis bullosa (DEB) should 
be the dermal fibroblast rather than 
the keratinocyte. These investigators 
provide evidence that when gene-cor-
rected DEB skin cells are conformed 
into a skin equivalent and transplant-
ed onto the backs of rodents, the type 
VII (anchoring fibril) collagen derived 
from dermal fibroblasts contributes 
more type VII to the basement mem-
brane zone (BMZ) at the dermal–epi-
dermal junction than do the gene-
corrected keratinocytes. This finding 
in vivo is interesting because in vitro 
it appeared that the gene-corrected 
DEB keratinocytes and fibroblasts 
they used expressed nearly equivalent 
amounts of type VII collagen. We and 
others have shown in vitro that both 
human keratinocytes and fibroblasts 
synthesize and excrete type VII colla-
gen (Stanley et al., 1985; Woodley et 
al., 1985; Ryynanen et al., 1992), but 
it was thought that in human beings 
in vivo most of the type VII collagen 
at the BMZ of the skin came from 
keratinocytes (Regauer et al., 1990). 
Goto and co-workers (2006) bring us 
good news, however, because der-
mal fibroblasts are much easier to 
work with and propagate than human 
keratinocytes. The conditions for cul-
turing human dermal fibroblasts are 
far less fastidious than those for cul-
turing human keratinocytes, so tech-
nical considerations are lessened. 
Fibroblasts are more robust cells than 
keratinocytes and are much less sus-
ceptible to growth arrest and differen-
tiation than epidermal sheets, which 
are fragile and must be used imme-
diately (Hengge and Bardenheuer, 
2004). Furthermore, fibroblasts can 
be passaged 20–30 times in vitro, 
are easy to grow in larger numbers, 
and can be readily cloned: a single 
genetically modified fibroblast can 
be expanded to greater than 1020 cells 
(Krueger, 2000).
In addition to the above consider-
ations favoring gene-corrected dermal 
fibroblasts over keratinocytes as targets 
for gene therapy in DEB, it has been 
shown that gene-corrected recessive 
DEB fibroblasts and normal human 
dermal fibroblasts can be injected 
intradermally into a rodent or into a 
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DEB skin equivalent transplanted onto 
a rodent, after which the cells export 
type VII collagen at the injection site. 
Once the exogenous exported col-
lagen is at the site, it attaches to the 
host’s BMZ and then forms anchoring 
fibril structures that correct the DEB 
phenotype in DEB skin equivalents 
(Oritz-Urda et al., 2003; Woodley et 
al., 2003). How this process occurs is 
not clear. We and others have shown 
that human type VII collagen has spe-
cific domains with affinity for other 
BMZ macromolecules including lam-
inin-5, fibronectin, and type IV colla-
gen (Champioaud et al., 1996; Chen et 
al., 1997; Chen et al., 1999). It is likely 
that the exported type VII collagen free 
in the extracellular spaces at the injec-
tion sites attaches to BMZ components 
and selectively adheres to the BMZ 
rather than remaining diffuse in the 
host’s dermis.
Although it is clear that Goto and 
co-workers (2006) have succeeded 
in delivering the human gene for full-
length type VII collagen into DEB fibro-
blasts and keratinocytes using a retrovi-
ral approach, there are some arguments 
that favor using lentiviral vectors over 
using retroviral vectors. First, lentiviral 
vectors can infect both dividing and 
non-dividing cells, whereas retroviruses 
can infect only dividing cells (Naldini, 
1998; Amado and Chen, 1999). One 
goal is to deliver the transgene to 
stem cells, which are also known to 
be slowly dividing cells; therefore, it 
would appear that lentiviruses would 
have an advantage over retroviruses. 
Consistent with this notion, a recent 
study compared the efficiency of gene 
transfer into human keratinocytes of 
adenoviral vectors, adenovirus-associ-
ated virus, retroviral vectors, and lenti-
viral vectors, the most commonly used 
viral vectors (Gagnoux-Palacios et 
al., 2005). Gagnoux-Palacios and co-
workers concluded that lentiviral vec-
tors were the most suitable for ex vivo 
gene therapy, because of their ability 
to transduce clonogenic primary kera-
tinocytes (Gagnoux-Palacios et al., 
2005). Secondly, lentiviral vectors pro-
vide high transduction efficiency and 
sustained gene expression in vivo. In 
the study by Goto et al. (2006), retrovi-
rus produced a maximum transduction 
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efficiency of about 30% without the 
help of retronectin, whereas lentivirus 
can produce transduction efficiency of 
over 90% in human skin cells (Chen 
et al., 2003). In a study comparing the 
efficiency of delivering human genes 
into skin cells by various methods, 
the lentivirus-mediated gene delivery 
approach was found to be the most effi-
cient (Chen et al., 2003). Nevertheless, 
maximal efficiency of delivering a col-
lagen gene may not be necessary in the 
treatment of DEB. This is because col-
lagens resist many proteases. Although 
the exact turnover time of type VII 
collagen in the skin is unknown, it is 
thought to be quite long, similar to that 
of other collagens (Burgeson, 1993). In 
addition, it has been shown that het-
erozygous patients with a COL7A1 null 
mutation may have a 50% reduction 
in the anchoring fibrils in their skin, 
yet there is no evidence of an epider-
molysis bullosa-like disease (Uitto and 
Christiano, 1994). This observation 
suggests that only 50% of the normal 
number of anchoring fibrils provides 
significant dermal–epidermal adher-
ence. However, the absolute minimal 
number of anchoring fibrils needed for 
“normal” dermal–epidermal adherence 
is not known. Finally, other advantages 
of lentiviral vectors should be men-
tioned. Lentiviral vectors can house 
very large human genes with little com-
promise of titers because of an ample 
cloning size of over 9 kb (Chen et al.). 
Further, lentiviral vectors do not appear 
to induce a significant host immune 
response, unlike adenoviral vectors.
The Goto et al. study (2006) also 
complements other recent studies on 
strategies for DEB therapy in that it 
shows again the plasticity of the biol-
ogy. Once this large, hockey stick-
shaped collagen is delivered to the 
extracellular space near the BMZ via 
intradermal injection, the collagen and 
its interaction with the host will figure 
everything else out, including how to 
get the exogenous collagen incorpo-
rated into the BMZ of the host, even 
across species. It has been shown that 
in addition to injecting fibroblasts into 
DEB models, one can also directly 
inject lentivirus harboring the human 
gene for type VII collagen intradermal-
ly into skin (Woodley et al., 2004b). 
These viruses then infect resident der-
mal cells in the area, including fibro-
blasts and endothelial cells, which 
then export the collagen into the extra-
cellular space. Once again, type VII 
collagen in the extracellular space will 
home to the BMZ, incorporate there, 
and form anchoring fibril structures 
(Woodley et al., 2004b). Perhaps even 
more interesting is the study showing 
that recombinant human type VII colla-
gen directly injected intradermally into 
an animal or into a DEB skin equiva-
lent grafted onto an animal will do 
the same thing — that is, home to the 
BMZ, incorporate there, make anchor-
ing fibril structures, and even correct 
the DEB phenotype (Woodley et al., 
2004a). This strategy has the advantage 
of simplicity, directness, and techni-
cal ease. Dermatologists are very well 
versed at injecting bovine or recombi-
nant type I collagen into human skin to 
improve fine rhytides. Therefore, it is 
theoretically feasible to inject recom-
binant type VII collagen into the high 
dermis of patients with DEB to restore 
type VII collagen and anchoring fibrils 
in their skin to reverse their skin fra-
gility and blistering. Again, because 
we do not know the turnover time of 
type VII collagen, we do not know how 
long type VII collagen and anchoring 
fibrils delivered by this method would 
last. How often would these injec-
tions have to be repeated to keep the 
anchoring fibrils at sufficient functional 
numbers to maintain the epidermolysis 
bullosa phenotype reversal? Delivering 
gene-corrected cells such as fibro-
blasts via cell therapy or lentiviral vec-
tors expressing type VII collagen may 
have the advantage of producing con-
tinuous type VII collagen α chains to 
the skin.
The other problem with all of these 
methods that require the intradermal 
injection of fibroblasts, vectors har-
boring the gene for type VII collagen 
within a viral system, or the recom-
binant protein itself is that many DEB 
patients have multiple wounds span-
ning large areas of trauma-prone sites 
such as the sacrum, hips, feet, lower 
back, and hands. These large areas 
would all need to be injected, proba-
bly repeatedly, although the injection 
time intervals are unknown. It would 
be advantageous to inject cells intra-
venously into the DEB patient, where 
they would home to the wound sites 
and deliver the transgene product. In 
this way, all of the patient’s wound 
areas could be replenished with type 
VII collagen and anchoring fibrils at the 
same time. We have been experiment-
ing with this model in the University 
of Southern California Laboratory for 
Investigative Dermatology.
In conclusion, the paper by Goto 
and colleagues (2006) supports the 
notion that fibroblasts are excellent tar-
gets for gene therapy for patients with 
DEB. They have many advantages over 
keratinocytes. Among these advan-
tages are their technical ease of use 
and the ability of exogenously deliv-
ered fibroblasts to reside where deliv-
ered and continuously deliver type 
VII collagen to the host’s BMZ, where 
it incorporates and forms anchoring 
fibril structures. These findings and a 
new appreciation for the plasticity of 
human skin biology should give hope 
to DEB patients and their families for 
improved therapy in the near future.
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